¼¼°èÀÇ ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDS) ½ÃÀå
Novel Drug Delivery Systems (NDDS)
»óǰÄÚµå : 1526364
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 492 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,104,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,312,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDS) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 655¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 163¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDS) ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2023-2030³â¿¡ 21.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 655¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ NDDS¿ë ³ª³ëÀÔÀÚ´Â CAGR 21.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 519¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. NDDS¿ë »öÀü ÀÔÀÚ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 24.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 57¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 26.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDS) ½ÃÀåÀº 2023³â¿¡ 57¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 74¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â°£ CAGRÀº 26.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 18.9%¿Í 19.9%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 20.3%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDS) ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDS)Àº ȯÀÚ¿¡°Ô ¾à¹°À» Àü´ÞÇÏ´Â Çõ½ÅÀûÀÎ ¹æ¹ýÀ¸·Î À¯È¿¼º, ¾ÈÀü¼º ¹× Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ È¯ÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÌ´Â ¹æ½ÄÀ¸·Î ¾à¹°À» Àü´ÞÇÏ´Â ¹æ¹ýÀ» ¸»ÇÕ´Ï´Ù. NDDS´Â ü³» ƯÁ¤ ºÎÀ§¿¡ Á÷Á¢ ¾à¹°À» Àü´ÞÇÏ¿© ¾à¹° ¹æÃâ ¼Óµµ¸¦ Á¦¾îÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á Áö¼ö¸¦ ÃÖ´ëÈ­Çϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç, ¸®Æ÷Á», ³ª³ëÀÔÀÚ, ¸¶ÀÌÅ©·Î´Ïµé, ¾à¹° ¿ëÃâ ½ºÅÙÆ® µî ´Ù¾çÇÑ ¾à¹° Àü´Þ Ç÷§ÆûÀÌ Æ÷ÇԵ˴ϴÙ. Àü´Þ Ç÷§ÆûÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ±â¼úÀº ¾à¹°ÀÇ Á¦¾îµÈ ¼­¹æÇü ¹æÃâÀ» °¡´ÉÇÏ°Ô Çϰí, Åõ¿© Ƚ¼ö¸¦ ÁÙ¿© ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß´Â ¸¸¼º Áúȯ ¹× ¾Ï Ä¡·á¿Í ¹é½Å Àü´Þ¿¡ ƯÈ÷ Áß¿äÇÕ´Ï´Ù.

¿¬±¸ÀÚµé°ú Á¦¾àȸ»çµéÀÌ ±âÁ¸ ¾à¹° Àü´Þ ¹æ¹ýÀÇ ÇѰ踦 ±Øº¹Çϱâ À§ÇØ ³ë·ÂÇϸ鼭 NDDSÀÇ °³¹ßÀº °è¼Ó ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ ¾à¹° Ä¡·áÀÇ Áß¿äÇÑ °úÁ¦ Áß Çϳª´Â ºÎÀÛ¿ëÀ» ÀÏÀ¸Å°Áö ¾Ê°í ¾à¹°ÀÇ ÃÖÀû Ä¡·á ¼öÁØÀ» ´Þ¼ºÇÏ´Â °ÍÀ̸ç, NDDS´Â ÷´Ü Á¦Çü ±â¼ú°ú ¿£Áö´Ï¾î¸µ ±â¼úÀ» ÅëÇØ ÀÌ °úÁ¦¸¦ ´Ü¼øÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ³ª³ëÀÔÀÚÀÇ EPR(Enhanced permeability and retention) È¿°ú´Â Á¾¾ç ¼¼Æ÷¿¡ ´ëÇÑ Ç¥ÀûÈ­µÈ ¾à¹° Àü´ÞÀ» °¡´ÉÇÏ°Ô ÇÏ¿© °Ç°­ÇÑ Á¶Á÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÃÖ¼ÒÈ­ÇÏ°í ¾Ï Ä¡·áÀÇ ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, NDDS¿¡ »ýºÐÇØ¼º ¼ÒÀ縦 Àû¿ëÇÏ¸é º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ ¾à¹° Àü´Þ ¸ÞÄ¿´ÏÁòÀ» ÃËÁøÇÒ ¼ö ÀÖ¾î Áö¼Ó °¡´ÉÇÑ ÀÇ·á ÇàÀ§¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ºÎÇÕÇÕ´Ï´Ù. ¶ÇÇÑ, ¼¾¼­°¡ ÀåÂøµÈ ½º¸¶Æ® ¾Ë¾à°ú °°Àº ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ µðÁöÅÐ ±â¼úÀ» ÅëÇÕÇÏ¸é ¾à¹° ¹æÃâ°ú ȯÀÚÀÇ º¹¾à ¼øÀÀµµ¿¡ ´ëÇÑ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, ÀÌ´Â Á¤È®ÇÑ ¿ë·®À» ÇÊ¿ä·Î ÇÏ´Â Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù.

½Å¾à Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº Àç·á°úÇаú »ý¸í°øÇÐÀÇ ±â¼ú ¹ßÀü, ¸¸¼ºÁúȯÀÇ È®»ê, ´õ ³ªÀº ¸ÂÃãÇü ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» ¿øÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ¼ÒºñÀÚÃþ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ³ª³ë±â¼ú°ú ºÐÀÚ»ý¹°ÇÐÀÇ ¹ßÀüÀº º¸´Ù È¿À²ÀûÀÎ ¾à¹° Àü´Þ ½Ã½ºÅÛ °³¹ß¿¡ Å« µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¾à¹°À» »ýü ÀûÇÕ¼º ¹°Áú¿¡ ĸ½¶È­ÇÏ¿© ½ÅüÀÇ ÀÚ¿¬Àû À庮À» ¿ìȸÇÏ¿© Áúº´ ºÎÀ§¿¡ Á÷Á¢, Á¦¾îµÈ ¼Óµµ·Î ¾à¹°À» ¹æÃâÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´, ½ÉÀ庴°ú °°Àº ¸¸¼º ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¸´Ù È¿À²ÀûÀÌ°í Æí¸®ÇÑ ¾à¹° Àü´Þ ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â NDDS ¿¬±¸°³¹ß¿¡ ´ëÇÑ Ãß°¡ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ȯÀÚµéÀÇ °Ç°­ °ü¸® ÀÇ»ç °áÁ¤¿¡ ´ëÇÑ Âü¿©°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÌ°í ºñħ½ÀÀûÀÌ¸ç Æí¸®ÇÑ ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú Çõ½ÅÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 238°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Novel Drug Delivery Systems (NDDS) Market to Reach US$65.5 Billion by 2030

The global market for Novel Drug Delivery Systems (NDDS) estimated at US$16.3 Billion in the year 2023, is expected to reach US$65.5 Billion by 2030, growing at a CAGR of 21.9% over the analysis period 2023-2030. Nanoparticles for NDDS, one of the segments analyzed in the report, is expected to record a 21.4% CAGR and reach US$51.9 Billion by the end of the analysis period. Growth in the Embolization Particles for NDDS segment is estimated at 24.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 26.6% CAGR

The Novel Drug Delivery Systems (NDDS) market in the U.S. is estimated at US$5.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2030 trailing a CAGR of 26.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.9% and 19.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 20.3% CAGR.

Global Novel Drug Delivery Systems (NDDS) Market - Key Trends and Drivers Summarized

Novel Drug Delivery Systems (NDDS) refer to innovative methods for delivering medication to patients in a manner that increases the efficacy, safety, and patient compliance with the treatment regimen. These systems are designed to target the delivery of drugs directly to a specific site in the body, control the rate of drug release, and maximize the therapeutic index while minimizing side effects. NDDS encompasses a variety of delivery platforms including liposomes, nanoparticles, microneedles, and drug-eluting stents, among others. These technologies enable controlled and sustained release of medications, potentially reducing dosage frequency and improving patient outcomes. This field is particularly significant in the treatment of chronic diseases, cancer, and for the delivery of vaccines.

The development of NDDS continues to grow as researchers and pharmaceutical companies aim to overcome the limitations of conventional drug delivery methods. One of the key challenges in traditional pharmacotherapy is achieving optimal therapeutic levels of a drug without causing adverse effects, a task that NDDS aims to simplify through advanced formulation and engineering techniques. Enhanced permeability and retention (EPR) effect of nanoparticles, for example, allows for targeted drug delivery to tumor cells, minimizing the impact on healthy tissues and reducing side effects in cancer treatments. Moreover, the application of biodegradable materials in NDDS promotes safer and more effective drug delivery mechanisms, aligning with the growing demand for sustainable medical practices. Additionally, the integration of digital technology into drug delivery systems, such as smart pills equipped with sensors, provides real-time data on drug release and patient adherence, which can be critical for treatments requiring precise dosages.

The growth in the Novel Drug Delivery Systems market is driven by several factors including technological advancements in material science and biotechnology, increasing prevalence of chronic diseases, and a more informed consumer base demanding better and more tailored healthcare solutions. Advancements in nanotechnology and molecular biology have been particularly instrumental in developing more efficient drug delivery systems. These innovations allow drugs to be encapsulated in biocompatible materials that can bypass the body's natural barriers and release drugs at a controlled rate directly at the disease site. Additionally, the rising incidence of chronic conditions such as diabetes and heart disease fuels the demand for more efficient and convenient drug delivery methods, encouraging further investment in NDDS research and development. Lastly, as patients become more engaged in their health care decisions, there is a growing demand for drug delivery systems that are not only effective but also non-invasive and convenient, steering the market towards sustained growth and innovation.

Select Competitors (Total 238 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â